根据最近向美国证券交易委员会(SEC)提交的8-K文件,医疗设备和服务提供商iRhythm Technologies, Inc.对其公司治理结构进行了重大修改。这家以外科和医疗器械板块工作而闻名的公司修订了其2016年股权激励计划,并更新了行为准则。 2024年11月7日,在薪酬和人力资本管理委员会的建议下,iRhythm董事会批准了对2016年股权激励计划的修订,取消了可发行股份数量的自动年度增 ...

近日，iRhythm Technologies, Inc.（纳斯达克股票代码：IRTC）的董事Abhijit Y.

iRhythm Technologies Inc. directors and executives harmed the medical device company by concealing shortcomings in its heart monitor’s performance, including transmission issues that led to two deaths ...

The FDA issued a warning letter to iRhythm in 2023 after a facility inspection revealed issues that included failing to seek clearance before making changes to the Zio system and marketing it for a ...

iRhythm Technologies reported third-quarter revenue that exceeded consensus estimates and the company's management has narrowed its revenue guidance for 2024. The growth in volume was widespread, with ...

However, iRhythm plans to postpone the regulatory filing for its Zio MCT product until the third quarter of 2025. This delay is expected to reduce sales estimates for 2025 by approximately $10 ...

Rhythm Technologies (Nasdaq:IRTC) announced that the FDA granted 510(k) clearance for Zio AT design modifications and ...

including design features and labeling updates intended to address areas of concern specific to Zio AT that were noted in a 2023 FDA warning letter to the Company,” said Quentin Blackford, iRhythm ...

Technologies announced that the U.S. FDA has granted clearance for its 510(k) submission related to design modifications and ...

SAN FRANCISCO - iRhythm Technologies, Inc. (NASDAQ:IRTC), a digital healthcare company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Zio AT device for upcoming ...